# A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

> **NCT07215923** · PHASE1 · RECRUITING · sponsor: **Antidote Therapeutics, Inc** · enrollment: 15 (estimated)

## Conditions studied

- Thromboangiitis Obliterans (Buerger's Disease)

## Interventions

- **BIOLOGICAL:** ATI-1013 (0.2 g)
- **BIOLOGICAL:** ATI-1013 (0.8 g)
- **BIOLOGICAL:** ATI-1013 (3.2 g)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07215923
- **Lead sponsor:** Antidote Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215923, "A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*